Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Glofitamab Humanized Recombinant Human Monoclonal Antibody
GREENER_CHOICE

Catalog No. PIMA542274
Change view
Click to view available options
Quantity:
100 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA542274 100 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Catalog No. PIMA542274 Supplier Invitrogen™ Supplier No. MA542274
Only null left
Add to Cart
Add to Cart
This item is not returnable. View return policy

Human Recombinant Monoclonal Antibody

Endotoxin level <0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Glofitamab is a biosimilar that targets CD3E.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Glofitamab Humanized
Applications ELISA, SDS-Page
Classification Recombinant Monoclonal
Concentration 1.69 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene Alias RG-6026
Host Species Human
Immunogen Human CD3E/MS4A1.
Purification Method Protein A/G
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG1 κ, IgG1 λ
Target Molecule Chemical
Show More Show Less
WARNING: Cancer - www.P65Warnings.ca.gov
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.